CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His, Avi), Biotinylated

Catalog No. TMPK-01003 Copy Product Info

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His, Avi), Biotinylated is expressed in HEK293 mammalian cells with N-His and C-Avi tag. The predicted molecular weight is 26.4 kDa and the accession number is Q5QGZ9-2.

CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His, Avi), Biotinylated

Catalog No. TMPK-01003

Copy Product Info

CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His, Avi), Biotinylated

Pack Size	Price	USA Stock	Global Stock
5 μg	$91	7-10 days	7-10 days
10 μg	$148	7-10 days	7-10 days
20 μg	$245	7-10 days	7-10 days
50 μg	$483	7-10 days	7-10 days
100 μg	$813	7-10 days	7-10 days
200 μg	$1,470	7-10 days	7-10 days
500 μg	$3,250	7-10 days	7-10 days

Add to Cart

Add to Quotation

In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	Immobilized Anti-CLEC12A Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human CLEC12A, His Tag with the EC50 of 0.41μg/ml determined by ELISA.
Description	CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His, Avi), Biotinylated is expressed in HEK293 mammalian cells with N-His and C-Avi tag. The predicted molecular weight is 26.4 kDa and the accession number is Q5QGZ9-2.
Species	Human
Expression System	HEK293 Cells
Tag	N-His, C-Avi
Accession Number	Q5QGZ9-2
Synonyms	PRO34150,MICL,HECL,DLEC,DCAL-2,DCAL2,CLL-1,CLL1,CLECSF7,CLECSF11,CLEC12A,CD371,CD303
Construction	His65-Ala265
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	26.4 kDa (predicted). Due to glycosylation, the protein migrates to 38-50 kDa based on Tris-Bis PAGE result.
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.